Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$819.1M
-6.1% from 2023
Prescriptions
1.4M
$591.96 per claim
Patients
291K
125,966 prescribers
Total spending, 2024
$819.3M
$2,813.43 per patient
Medicare prescription drug plans paid $819.1M for Anoro Ellipta in 2024, for 1,383,640 prescriptions and refills to 291,120 patients (down 6.1% from 2023). The average cost per claim was $591.96.
Pennsylvania had the highest Medicare cost for Anoro Ellipta in 2024: $62.6M for 110,644 claims, followed by New York ($62.6M).
Kenneth K Sha, pulmonary disease in Flushing, NY, had the highest Medicare cost for Anoro Ellipta in 2024: 1,274 claims costing $605K.
Anoro Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Kenneth K Sha Flushing, NY | Pulmonary Disease | 1,274 | 232 | $605K |
| Singwu D Law New York, NY | Pulmonary Disease | 1,122 | 182 | $527K |
| Chih M Chen Springfield, MA |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 117,136 | 1,439,562 | 297,055 | $866.6M |
| 2023 | 121,723 | 1,389,702 | 294,360 | $872.6M |
| 2024 | 125,966 | 1,383,640 | 291,120 | $819.1M |
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Hospitalist |
| 703 |
| 132 |
| $375K |
| Bobby Shah Chesterfield, MO | Pulmonary Disease | 616 | 140 | $365K |
| Sridhar H Dasari Abington, MA | Pulmonary Disease | 361 | 121 | $346K |
| Nizar C Issa Forrest City, AR | Pulmonary Disease | 479 | 128 | $330K |
| Asaf Savir Carmel, NY | Pulmonary Disease | 312 | 91 | $301K |
| Bryson P Stair Columbus, OH | Nurse Practitioner | 609 | 106 | $300K |
| John E Daniels Wauwatosa, WI | Pulmonary Disease | 516 | 102 | $300K |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 324 | 108 | $293K |
| Chitra Kandaswamy Fresno, CA | Pulmonary Disease | 606 | 193 | $280K |
| Preston G Thornhill Tifton, GA | Nurse Practitioner | 380 | 96 | $277K |
| Sergio L Balingit Jr. The Villages, FL | Pulmonary Disease | 382 | 94 | $273K |
| Howard Steiner Baltimore, MD | Pulmonary Disease | 311 | 78 | $270K |
| Diego A Maldonado Vero Beach, FL | Critical Care (Intensivists) | 316 | 91 | $267K |
| Michael A Imevbore New Haven, CT | Pulmonary Disease | 310 | 89 | $264K |
| Marc D Laufe Naples, FL | Pulmonary Disease | 239 | 74 | $261K |
| Magdy Mostafa Silvis, IL | Pulmonary Disease | 466 | 76 | $260K |
| Peter Serpico Yardley, PA | Pulmonary Disease | 408 | 77 | $251K |
| Laurie A Kilkenny Pittsburgh, PA | Critical Care (Intensivists) | 442 | 81 | $249K |
| Naveen R Kanathur Bettendorf, IA | Pulmonary Disease | 462 | 92 | $247K |
| Steven M Geller Philadelphia, PA | Pulmonary Disease | 467 | 82 | $246K |
| Caroline Hendley Adel, GA | Nurse Practitioner | 330 | 89 | $242K |
| Jessica B Moja Springfield, IL | Pulmonary Disease | 454 | 78 | $242K |
| Ladly Abraham Conway, AR | Pulmonary Disease | 448 | 88 | $240K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline GSK | 1,383,988 | $819.3M |